DSAM Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

DSAM Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-2,583	Closed	-$369K	–	108
2019 Q1	$369K	Buy	+2,583	New	+$337K	0.05%	58

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

DSAM Partners's JAZZ Position: Q2 2019 in Review

DSAM Partners sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2019, closing a stake of 2,583 shares — an estimated $369K sold.

DSAM Partners first reported a position in JAZZ in Q1 2019 and held it in 1 quarter. The position peaked at $369K in Q1 2019. 416 funds tracked by Wall St. Rank hold JAZZ as of Q2 2019.

DSAM Partners reported no remaining Jazz Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
DSAM Partners sold 2,583 Jazz Pharmaceuticals shares in Q2 2019, an estimated $369K.
DSAM Partners first reported a position in Jazz Pharmaceuticals in Q1 2019 and held it in 1 quarter.
DSAM Partners's Jazz Pharmaceuticals position peaked at $369K in Q1 2019.
416 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2019.

Based on DSAM Partners's 13F filing for Q2 2019, filed 14 Aug 2019.